| Controls (n = 20) | TREACH (n = 38) | FLARE (n = 37) |
---|---|---|---|
Female gender, n (%) | 10 (50) | 25 (65.8) | 25 (67.6) |
Age in years, mean (SD) | 31.8 (9.7) | 53.3 (13.98)a | 53.7 (13.40)a |
Disease duration in months, median (range) | - | 5.4 (2-12) | 73.0 (0-414)b |
Presence of joint erosions, n (%) | - | 10 (26.3) | 20 (54.1)c |
Anti-CCP positive, n (%) | - | 30 (78.9) | 24 (85.7)d |
Rheumatoid factor (IgM) positive, n (%) | - | 31 (81.6) | 27 (73.0) |
DAS44 at baseline, mean (SD) | - | 3.05 (0.92) | 3.57 (0.95)c |
HAQ-DI at baseline, mean (SD) | - | - | 1.43 (0.62) |
Use of NSAID, n (%) | - | 25 (67.6) | 19 (51.4) |
Use of methotrexate, n (%) | - | - | 22 (59.5) |
Use of hydroxychloroquine, n (%) | - | - | 11 (29.7) |
Use of sulfasalazine, n (%) | - | - | 5 (13.5) |
Number of DMARDs, median (range) | - | - | 1 (0-3)e |
Use of anti-TNF-α therapy, n (%) | - | - | 5 (13.5) |